[go: up one dir, main page]

WO2010094981A3 - Antibody therapy - Google Patents

Antibody therapy Download PDF

Info

Publication number
WO2010094981A3
WO2010094981A3 PCT/GB2010/050304 GB2010050304W WO2010094981A3 WO 2010094981 A3 WO2010094981 A3 WO 2010094981A3 GB 2010050304 W GB2010050304 W GB 2010050304W WO 2010094981 A3 WO2010094981 A3 WO 2010094981A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antibody therapy
cathepsin
antibody molecule
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2010/050304
Other languages
French (fr)
Other versions
WO2010094981A2 (en
Inventor
Shane Olwill
Richard Buick
Hang Fai Kwok
James Johnston
Christopher Scott
Claire Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Antibodies Ltd
Original Assignee
Fusion Antibodies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Antibodies Ltd filed Critical Fusion Antibodies Ltd
Publication of WO2010094981A2 publication Critical patent/WO2010094981A2/en
Publication of WO2010094981A3 publication Critical patent/WO2010094981A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Described are methods of inhibiting angiogenesis, the methods comprising the simultaneous, sequential or separate administration of (i) an anti- Cathepsin S antibody molecule, and (ii) an anti-VEGF antibody molecule. Also described are anti-Cathepsin S humanised antibodies, pharmaceutical compositions and methods of treatment using such antibodies.
PCT/GB2010/050304 2009-02-20 2010-02-22 Antibody therapy Ceased WO2010094981A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0902916.6 2009-02-20
GBGB0902916.6A GB0902916D0 (en) 2009-02-20 2009-02-20 Antibody therapy

Publications (2)

Publication Number Publication Date
WO2010094981A2 WO2010094981A2 (en) 2010-08-26
WO2010094981A3 true WO2010094981A3 (en) 2010-12-23

Family

ID=40565474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/050304 Ceased WO2010094981A2 (en) 2009-02-20 2010-02-22 Antibody therapy

Country Status (2)

Country Link
GB (1) GB0902916D0 (en)
WO (1) WO2010094981A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063395A1 (en) * 2011-10-27 2013-05-02 Nkt Therapeutics Inc. Humanized antibodies to inkt
AR114732A1 (en) 2018-09-18 2020-10-07 Hoffmann La Roche USE OF A CATEPSIN S INHIBITOR AGAINST THE FORMATION OF ANTI-DRUG ANTIBODIES
CN114989297B (en) * 2022-06-14 2022-10-25 北京科跃中楷生物技术有限公司 Kit comprising horseradish peroxidase-labeled antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109045A2 (en) * 2005-04-09 2006-10-19 Fusion Antibodies Limited Cathepsin s antibody
WO2008044076A2 (en) * 2006-10-12 2008-04-17 Fusion Antibodies Limited Therapy targeting cathepsin s

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
ATE297465T1 (en) 1991-11-25 2005-06-15 Enzon Inc METHOD FOR PRODUCING MULTIVALENT ANTIGEN-BINDING PROTEINS
JP3285355B2 (en) 1992-06-04 2002-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and compositions for in vivo gene therapy
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109045A2 (en) * 2005-04-09 2006-10-19 Fusion Antibodies Limited Cathepsin s antibody
WO2008044076A2 (en) * 2006-10-12 2008-04-17 Fusion Antibodies Limited Therapy targeting cathepsin s

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BURDEN ROBERTA E ET AL: "Antibody-Mediated Inhibition of Cathepsin S Blocks Colorectal Tumor Invasion and Angiogenesis", CLINICAL CANCER RESEARCH, vol. 15, no. 19, October 2009 (2009-10-01), pages 6042 - 6051, XP002583183, ISSN: 1078-0432 *
MACCALLUM R M ET AL: "Antibody-antigen interactions: Contact analysis and binding site topography", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB LNKD- DOI:10.1006/JMBI.1996.0548, vol. 262, no. 5, 1 January 1996 (1996-01-01), pages 732 - 745, XP002242391, ISSN: 0022-2836 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.79.6.1979, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424 *
TOL JOLIEN ET AL: "Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US LNKD- DOI:10.1056/NEJMOA0808268, vol. 360, no. 6, 1 February 2009 (2009-02-01), pages 563 - 572, XP002526064, ISSN: 0028-4793 *
VAJDOS F F ET AL: "Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB LNKD- DOI:10.1016/S0022-2836(02)00264-4, vol. 320, no. 2, 5 July 2002 (2002-07-05), pages 415 - 428, XP004449739, ISSN: 0022-2836 *
WU HERREN ET AL: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY,, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 151 - 162, XP002582261 *

Also Published As

Publication number Publication date
GB0902916D0 (en) 2009-04-08
WO2010094981A2 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
WO2011003557A8 (en) A complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
WO2011110642A3 (en) Monoclonal antibodies against c-met
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
WO2010066803A3 (en) Human antibodies against human tissue factor
EP4434550A3 (en) Human antibody drug conjugates against tissue culture
WO2011160119A8 (en) Anti-gd2 antibodies
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
IL212633A (en) Monoclonal antibody or antigen-binding fragment thereof, pharmaceutical compositions comprising the same and use thereof for the manufacture of medicaments for the treatment of cancer
EP3539988A3 (en) Monoclonal antibodies against her2
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
JOP20210044A1 (en) Anti-CD38 . antibody
WO2008121615A3 (en) Antibody formulation
AU2009301431A8 (en) Bispecific anti-VEGF/anti-ANG-2 antibodies
MX350200B (en) Human antibodies and antibody-drug conjugates against cd74.
MX2014001372A (en) Pharmaceutical composition for treatment and/or prevention of pancreatic cancer.
WO2009112245A9 (en) Antibody against the csf-1 r
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
MX2013000958A (en) Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma.
EA201290849A1 (en) OPTIMIZED MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR (TFPI)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10706043

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10706043

Country of ref document: EP

Kind code of ref document: A2